Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma and Controls

26 juillet 2016 mis à jour par: University of Pittsburgh

Procurement of Central Nervous System and Extracranial Tumor Tissues, Cerebrospinal Fluid, and Serum/Plasma From Patients With Metastatic Melanoma to the CNS and Respective Controls for Gene Expression and Proteomic Profiling

This study has two ultimate goals:

  1. Understand how the original melanoma from the skin spreads to the CNS. In order to study this we need to collect (and compare) the original skin melanoma, the CNS melanoma, as well as any other melanoma that has not metastasized to the CNS.
  2. Develop a diagnostic blood test that will early identify subjects at high risk for developing CNS metastasis or patients who may already have CNS metastasis but the MRI or the CAT scan cannot yet detect it. Thus, the investigators plan to collect CSF from subjects like you who have melanoma CNS metastases in order to confirm the presence of this biomarker.

Aperçu de l'étude

Statut

Retiré

Type d'étude

Observationnel

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Primary care clinic

La description

Inclusion Criteria:

  1. Regarding patients with distant metastatic melanoma and established melanoma CNS metastases who are scheduled for craniotomy:

    • Histologically confirmed, primary cutaneous melanoma, metastatic to the CNS (brain OR spinal cord OR carcinomatous meningitis) based on:

      • Pathologic confirmation (i.e. prior craniotomy) OR
      • Radiography (brain MRI or CT scan with intravenous contrast)
    • Patients must have no contraindications for and be able to undergo lumbar puncture for CSF collection
    • Hemoglobin level of 8g/dL or higher. This can be drawn on the day of consent, or will be acceptable if documented from a previous visit within the prior 30 days
    • Subjects must have provided written, informed consent (ICF) prior to any study procedures
    • Subjects must provide a FFPE tissue block containing a biopsy from the primary site
  2. Regarding patients with distant metastatic melanoma and established melanoma CNS metastases who are not having a craniotomy and before they undergo external beam irradiation or stereotactic radiosurgery (patient's and/or neurosurgeon's preference):

    • Histologically confirmed melanoma (unknown primary, mucosal, ocular are allowed), metastatic to the CNS (brain OR spinal cord OR carcinomatous meningitis) based on

      • Pathologic confirmation (i.e. prior craniotomy) and/or
      • Radiography (brain MRI or CT scan with intravenous contrast)
    • Patients must have no contraindications for and be able to undergo lumbar puncture for CSF collection
    • Hemoglobin level of 8g/dL or higher. This can be drawn on the day of consent, or will be acceptable if documented from a previous visit within the prior 30 days
    • Subjects must have provided written ICF prior to any study procedures
  3. Regarding patients who have distant metastatic melanoma without radiographically detectable melanoma CNS metastases but are willing to undergo lumbar puncture:

    • Histologically confirmed melanoma (unknown primary, mucosal, ocular are allowed),
    • Patients must have no contraindications to lumbar puncture
    • Hemoglobin level of 8g/dL or higher. This can be drawn on the day of consent, or will be acceptable, if documented from a previous visit within the prior 30 days
    • Subjects must have provided written ICF prior to any study procedures
  4. Regarding healthy volunteers

    • Patients must have no contraindications to lumbar puncture (see Table 1)
    • Patient must answer NO to all questions listed in Appendix B
    • Hemoglobin level of 8g/dL or higher. This can be drawn on the day of consent or will be acceptable if documented from a previous visit within the prior 30 days
    • Subjects must have provided written, ICF prior to any study procedures

Exclusion Criteria:

  • For study subjects, patients with extradural lesions, i.e. those that originate from the bone (calvarium or vertebrae), will not be considered.
  • Any significant psychiatric disease, medical intervention, or other conditions, which in the opinion of the Investigators, could impair proper discussion of the informed consent or compromise participation to the clinical trial.
  • Active systemic treatment for metastatic melanoma within 2 days from the collection of specimens (brain tumor tissue, peripheral blood, CSF). Corticosteroids, other immunosuppressive anti-inflammatory and anti-epileptic medications are allowed.
  • Patients who have undergone whole brain irradiation therapy within the last 30 days. Therefore neither CNS lesions nor CSF are considered suitable for collection.
  • Patients with growing CNS lesions at an area that has previously undergone radiosurgery within 3 months prior to enrollment in this study. Therefore CNS tumors from previously irradiated areas using radiosurgery are not considered suitable for collection although CSF is allowed for collection.
  • Brain abscess.
  • Patients with new focal findings on neurological examination.
  • Infected skin over the lumbar puncture needle entry site.
  • Other conditions that at the opinion of the investigator are contraindicated.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: Cas-témoins
  • Perspectives temporelles: Éventuel

Cohortes et interventions

Groupe / Cohorte
Subjects undergoing a craniotomy
This group will include those subjects who have consented to have either a craniotomy or a laminectomy to resect an intramedullary tumor.
Metastases, no craniotomy
These subjects have metastases but have either chosen not to undergo removal of the cancer or their neurosurgeon does not recommend surgical approach or they have been diagnosed with metastatic melanoma but do not have CNS metastases.
Healthy Volunteers
Subjects who do not have known melanoma or metastases.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Stergios Moschos, MD, University of Pittsburgh

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 juillet 2012

Achèvement primaire (Réel)

1 juillet 2012

Achèvement de l'étude (Réel)

1 novembre 2012

Dates d'inscription aux études

Première soumission

8 mars 2011

Première soumission répondant aux critères de contrôle qualité

8 mars 2011

Première publication (Estimation)

10 mars 2011

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

27 juillet 2016

Dernière mise à jour soumise répondant aux critères de contrôle qualité

26 juillet 2016

Dernière vérification

1 juillet 2016

Plus d'information

Termes liés à cette étude

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner